Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Histamine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH1 known ✓ | P35367 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | HTR1A | P08908 | 1/20 | 0.38 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.38 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.38 |
| ▸ | HTR1B | P28222 | 1/20 | 0.38 |
| ▸ | HTR2C | P28335 | 1/20 | 0.38 |
| ▸ | HTR1E | P28566 | 1/20 | 0.38 |
| ▸ | HTR7 | P34969 | 1/20 | 0.38 |
| ▸ | HTR5A | P47898 | 1/20 | 0.38 |
| ▸ | HTR6 | P50406 | 1/20 | 0.38 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.38 |
| ▸ | BLM | P54132 | 4/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.35 |
| ▸ | RAD52 | P43351 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Histamine SCHEMBL27177427 | 0.98 | TDP1 (0.37) | TDP1LMNAHTR1AADRA2ASLC6A2 | |
| Histamine SCHEMBL5171138 | 0.94 | LMNA (0.38) | TDP1LMNAHTR1AADRA2ASLC6A2 | |
| Histamine SCHEMBL1782847 | 0.90 | HRH4 (0.36) | TDP1LMNAHTR7TSHRCYP2C9 | |
| Histamine SCHEMBL748689 | 0.89 | LMNA (0.32) | TDP1LMNATSHRCYP2C9CYP2C19 | |
| Histamine SCHEMBL4234179 | 0.88 | HRH4 (0.39) | TDP1LMNASMN1; SMN2TSHRCYP2C9 | |
| Histamine SCHEMBL8887482 | 0.86 | HRH4 (0.34) | TDP1TSHRCYP2C9CYP2C19MTOR | |
| Histamine SCHEMBL5840054 | 0.86 | HRH4 (0.38) | TDP1HTR1AHTR1BTSHRCYP2C9 | |
| Histamine SCHEMBL5321413 | 0.85 | LMNA (0.33) | TDP1LMNASLC6A2BLMNPSR1 | |
| Maleic Acid SCHEMBL2138427 | 0.85 | KDM4E (0.33) | BLMNPSR1MEN1KMT2AKDM4E | |
| Histamine SCHEMBL1680140 | 0.85 | LMNA (0.33) | TDP1LMNASLC6A2BLMNPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101626015-A | Packaging structure, forming method thereof, mass production method thereof and chip stacking structure | NANMAO SCI & TECH CO LTD | 2010-01-13 | — | — | CN | claimed |
| EP-0502314-B1 | Benzimidazol derivatives, medicaments containing them and process for their preparation | THOMAE GMBH DR K (DE) | 1998-05-20 | — | — | EP | claimed |
| EP-0468470-B1 | Benzimidazoles, medicaments containing them and process for their preparation | THOMAE GMBH DR K (DE) | 1997-04-16 | — | — | EP | claimed |
| US-5587393-A | ANGIOTENSIN ANTAGONIST USEFUL IN TREATING HYPERTENSION | DR. KARL THOMAE GMBH (DE) | 1996-12-24 | — | — | US | claimed |
| US-5459147-A | Angeotensin-antagonistic effects; hypotensive, antiischemic, and antidiabetic agents, treating glaucoma | DR. KARL THOMAE GMBH (DE) | 1995-10-17 | — | — | US | claimed |
| US-9668973-B2 | Components for producing amphoteric liposomes | MARINA BIOTECH, INC. (US) | 2017-06-06 | — | — | US | disclosed |
| US-20140227345-A1 | COMPONENTS FOR PRODUCING AMPHOTERIC LIPOSOMES | MARINA BIOTECH, INC. (US) | 2014-08-14 | — | — | US | disclosed |
| CN-102543961-B | Package with electrostatic damage and electromagnetic interference prevention and manufacturing method thereof | SILICONWARE PRECISION INDUSTRIES CO LTD | 2014-08-13 | — | — | CN | disclosed |
| CN-102376592-B | Chip scale package and fabrication method thereof | SILICONWARE PRECISION INDUSTRIES CO LTD | 2014-05-07 | — | — | CN | disclosed |
| US-8580297-B2 | Components for producing amphoteric liposomes | MARINA BIOTECH, INC. (US) | 2013-11-12 | — | — | US | disclosed |
| CN-102543961-A | Package with electrostatic damage and electromagnetic interference prevention and manufacturing method thereof | SILICONWARE PRECISION INDUSTRIES CO LTD | 2012-07-04 | — | — | CN | disclosed |
| US-20120100205-A1 | COMPONENTS FOR PRODUCING AMPHOTERIC LIPOSOMES | MARINA BIOTECH, INC. | 2012-04-26 | — | — | US | disclosed |
| US-5594003-A | HYPOTENSIVE AGENTS | DR. KARL THOMAE GMBH (DE) | 1997-01-14 | — | — | US | disclosed |
| US-5591762-A | HYPOTENSIVE AGENTS | DR. KARL THOMAE GMBH (DE) | 1997-01-07 | — | — | US | disclosed |
| US-5587393-A | ANGIOTENSIN ANTAGONIST USEFUL IN TREATING HYPERTENSION | DR. KARL THOMAE GMBH (DE) | 1996-12-24 | — | — | US | disclosed |
| US-5565469-A | HYPOTENSIVE AGENTS | DR. KARL THOMAE GMBH (DE) | 1996-10-15 | — | — | US | disclosed |
| US-5519138-A | ANGIOTENSIN ANTAGONIST | DR. KARL THOMAE GMBH (DE) | 1996-05-21 | — | — | US | disclosed |
| US-5459147-A | Angeotensin-antagonistic effects; hypotensive, antiischemic, and antidiabetic agents, treating glaucoma | DR. KARL THOMAE GMBH (DE) | 1995-10-17 | — | — | US | disclosed |
| US-5385925-A | Benzimidazoles, pharmaceutical compositions containing these compounds and processes for preparing them | DR. KARL THOMAE GMBH (DE) | 1995-01-31 | — | — | US | disclosed |
| CN-1057911-A | Form the coupling agent of weld and the color silver halide photographic-material that contains this coupling agent | FUJI PHOTO FILM CO LTD (JP) | 1992-01-15 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140227345-A1 | COMPONENTS FOR PRODUCING AMPHOTERIC LIPOSOMES | PHOSPHO1, SGMS1, CHMP4B | HRH1 1053/4885TDP1 4568/4885LMNA 324/4885 |
| US-20120100205-A1 | COMPONENTS FOR PRODUCING AMPHOTERIC LIPOSOMES | PHOSPHO1, SGMS1, CHMP4B | HRH1 1053/4885TDP1 4568/4885LMNA 324/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.